Neurogastrx
Cyril, a Neurogastrx co-founder, has more than 20 years of drug development experience, having led multiple programs from IND submission to late-stage clinical development. Before Neurogastrx, Cyril led the division at Kinemed responsible for advising global and venture backed pharmaceutical companies on neuroscience drug development programs. Prior to Kinemed, he led clinical development programs targeting neurological disorders at Jazz Pharmaceuticals and served as a senior research scientist at Amgen and Roche Pharmaceuticals. These experiences led him to explore the role of the enteric nervous system in GI conditions, such as gastroparesis, the focus of our NG-101 development program. Cyril has a Master of Science in Pharmacology and a doctorate in Neuroscience from the University of Montpellier in France.
This person is not in any offices
Neurogastrx
Neurogastrx is a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. They focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden.